canadian blood services is pleased to announces its 2018 blood efficiency accelerator award program competition. the objective of the program is to improve the efficient and appropriate utilization of blood products, while maintaining the safety of the blood system.

for detailed information about the blood efficiency accelerator award program competition, please refer to www.blood.ca. the deadline to submit completed application packages is july 15 2018.

to stay informed about canadian blood services’ centre for innovation funding opportunities, please sign up for our research & education newsletter.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) j9, research and development directorate, manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

all applications for prmrp funding must specifically address at least one of the topic areas as directed by congress and must be directly relevant to the healthcare needs of military service members, veterans, and/or beneficiaries.  if the proposed research does not specifically address at least one of the fy18 prmrp topic areas, the government will administratively withdraw the application.  the government reserves the right to reassign the application’s topic area if submitted under an inappropriate topic area.  the fy18 prmrp topic areas are listed below.

the mission of the prmrp is to encourage, identify, and select military health-related research of exceptional scientific merit. relevance to the healthcare needs of military service members, veterans, and their family members is a key feature of each fy18 prmrp award mechanism.

http://cdmrp.army.mil/funding/prmrp

discovery award – letter of intent due june 14, 2018

·         postdoctoral fellow or clinical fellow (or equivalent) and above.

• supports the exploration of a highly innovative new concept or untested theory in the topic area(s) of interest.
• not intended to support the logical progression of an already established line of questioning.
• clinical trials will not be funded.

·         reviewers will be blinded to the identity of the principal investigator (pi), collaborator(s), and their organization(s).

• maximum of $200,000 for direct costs (plus indirect costs)

·         maximum period of performance is 18 months

focused program award – preproposal due june 19, 2018

·         lead pi: full professor level or above (or equivalent)

·         project leads: assistant professor level or above (or equivalent)

• preproposal submission is required; application submission is by invitation only.
• supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal in the topic area(s) of interest.
• projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
• projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.

·         research team of highly qualified, multidisciplinary project leaders should be led by a pi with demonstrated success in directing large, focused projects.

• maximum of $10 million for total costs (includes direct and indirect costs)

·         maximum period of performance is 4 years

investigator-initiated research award – preproposal due june 12, 2018

·         assistant professor level or above (or equivalent)

• preproposal submission is required; application submission is by invitation only.
• supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
• partnering pi option available.

·         clinical trials will not be funded.

• maximum of $1.2 million for direct costs (plus indirect costs)
• maximum of $1.5 million for direct costs (plus indirect costs) for applications including a partnering pi option

·         maximum period of performance is 3 years

technology/ therapeutic development award – preproposal due june 12, 2018

·         assistant professor level or above (or equivalent)

• supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the topic area(s) of interest.
• product-oriented (e.g., device, drug, clinical guidelines). the product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
• clinical trials will not be funded.

·         preproposal submission is required; application submission is by invitation only.

• maximum of $3.0 million for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

·          

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions that are available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

applications must be submitted through the federal government's single-entry portal, grants.gov. for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the prmrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the banting postdoctoral fellowships program provides funding to the very best postdoctoral applicants, both nationally and internationally, who will positively contribute to the country's economic, social and research-based growth.

the objective of the banting postdoctoral fellowships program is to:

• attract and retain top-tier postdoctoral talent, both nationally and internationally
• develop their leadership potential
• position them for success as research leaders of tomorrow

value & duration

• $70,000 per year (taxable)
• 2 years (non-renewable)

next important date

application submission deadline:
september 19, 2018 (20:00 edt)

• if you are successful with a banting, the vp (ri) will contribute a minimum of $5,000.  in addition, the vp (ri) will contribute an additional $2,500 if matched by an additional $2,500 from the respective faculty dean for a potential institutional contribution of $10,000.  the match from the dean must be requested by  pdf supervisors and confirmed in writing.
• as well, applicants work will be required to work with either our sshrc or nserc/cihr research facilitator when developing their proposals.

global affairs canada has launched a call for preliminary proposals to enhance economic empowerment, well-being and inclusive economic growth for women in ghana. the deadline for submitting a preliminary proposal is 12 p.m. (noon) eastern daylight time on june 6, 2018.

eligibility: canadian and ghanaian organizations 
geographic scope: ghana 
estimated size of projects sought: $5 million to $10 million

as organizations can only submit one application to this competition, interested applicants are asked to contact the office of  research (ahacquo1@lakeheadu.ca) no later than may 6 if they are interested in applying to this opportunity.

the vision of als canada is to make als a treatable, not terminal, disease. research is the pathway to achieve this. each year, we provide canada’s als research community with opportunities to apply for research funding from als canada.

canadian research efforts have helped to advance treatment discoveries and shed light on the complex genetic and environmental factors involved in als. we will continue to fund the best als research in canada to accelerate progress even further.

in the context of improved health for canadians, the objectives of the collaborative health research projects (chrp) initiative are to:

• translate research results to knowledge/technology users (ktus) and other stakeholders;
• encourage the natural sciences and/or engineering and health research communities to collaborate and integrate their expertise;
• advance interdisciplinary research leading to knowledge and technologies;
• benefit canada by improving the canadian healthcare system and/or services;
• lead to economic opportunities in canada (where appropriate); and
• provide training opportunities in collaborative and interdisciplinary research of relevance to health, while preparing them for employment opportunities in the private, public or not for profit sectors.

the epac collaborative will advance the shared priority of providing end-of-life care for both residents and their families in their homes, including support for all affected by the death of that resident.